key: cord-0892162-5l9qwhg3
authors: Del Amo, J.
title: Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers
date: 2022-03-04
journal: nan
DOI: 10.1101/2022.03.02.22271710
sha: 68dbc9db62526155e37578602ca60effdd9971ac
doc_id: 892162
cord_uid: 5l9qwhg3

Objective: To assess the effect of hydroxychloroquine (HCQ), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC), and their combination as pre-exposure prophylaxis on the risk of symptomatic COVID-19. Methods: EPICOS is a double-blind, placebo-controlled randomized trial conducted in 51 hospitals in Spain, Bolivia, and Venezuela. Healthcare workers with negative SARS-CoV-2 IgM/IgG test were randomly assigned to: daily TDF/FTC plus HCQ for 12 weeks, TDF/FTC plus HCQ placebo, HCQ plus TDF/FTC placebo and TDF/FTC placebo plus HCQ placebo. The primary outcome was laboratory-confirmed, symptomatic COVID-19. We also studied any (symptomatic or asymptomatic) COVID-19 infection. We compared group-specific 14-week risks via differences and ratios with 95% confidence intervals (CI). Results: Of 1002 individuals screened, 926 (92.4%) were eligible; 64.2% recruited in Spain, 22.3% in Bolivia, and 13.6% in Venezuela. Median age was 38 years (range 18 - 68), 62.5% were female, 62.3% worked at inpatient care, and comorbidities were rare. Compared with the placebo group, 14-week risk ratios (95% CI) of symptomatic COVID-19 were 0.39 (0.00, 1.98) for TDF+HCQ, 0.34 (0.00, 2.06) for TDF, and 0.49 (0.00, 2.29) for HCQ. Corresponding risk ratios of any COVID-19 were 0.51 (0.21, 1.00) for TDF+HCQ, 0.81 (0.44, 1.49) for TDF, and 0.73 (0.41, 1.38) for HCQ. Adverse events were generally mild. Conclusion: A beneficial effect of TDF/FTC and HCQ, alone or in combination, as pre-exposure prophylaxis for COVID-19 cannot be ruled out but effect estimates are imprecise because the target sample size was not met. These findings support launching randomized trials of TDF/FTC for the early treatment of COVID-19.

The repurposing of drugs as prophylactic agents against COVID-19 started early in the pandemic (1) . Based largely on in-vitro evidence suggesting hydroxychloroquine (HCQ) may block viral and cell fusion, randomized trials of HCQ as pre-exposure prophylaxis were among the earliest to be launched (1) (2) (3) (4) (5) . However, these trials were small and resulted in imprecise effect estimates (2) (3) (4) (5) . Tenofovir disoproxil fumarate (TDF) was another appropriate candidate to test in clinical trials based on epidemiological data suggesting a protective effect against severe COVID-19 (6-7), in-vitro studies reporting inhibition of the SARS-CoV-2 RNA-dependent RNA-polymerase (8) (9) (10) (11) (12) (13) ) and its high bioavailability in many tissues (14-16). However, no randomized trials of TDF for pre-exposure prophylaxis have been completed.

Both hydroxychloroquine and TDF are generic drugs widely prescribed worldwide. HCQ has been used as treatment and prophylaxis of malaria. TDF, in combination with emtricitabine (FTC), has been used for the treatment and prophylaxis of HIV infection. Both drugs have a proven, and well documented, safety record (17) (18) (19) . Despite their potential for massive use against COVID-19, these safe and inexpensive drugs have not been studied in randomized trials (TDF) or the randomized trials have been relatively small (HCQ).

We carried out a double-blind placebo-controlled randomized trial to assess the effect of daily HCQ or TDF/FTC, and of their combination, during 12 weeks as pre-exposure prophylaxis against COVID-19 in healthcare workers. Here we report estimates of effect and safety.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 4, 2022. ;  https://doi.org/10.1101/2022.03.02.22271710 doi: medRxiv preprint Methods EPICOS (NCT04334928, EudraCT number 2020-001385-11) was a multicenter, doubleblind, placebo-controlled randomized trial to study the effect of TDF/FTC and HCQ as preexposure prophylaxis for symptomatic COVID-19 among healthcare workers in Spain, Bolivia and Venezuela. The trial was designed to recruit 4000 individuals, but the start of the vaccination campaign and other factors limited recruitment to 907 participants.

Recruitment into the trial was actively promoted in Spain through regional health authorities, the Ministry of Health and in Latin America through Esther (Ensemble de Solidarité Thérapeutique Hospitalière En Reseau). Healthcare workers were approached individually and collectively through promotional in-hospital sessions, mailings and hospital-wide advertisements. A mobile phone app was developed for electronic monitoring, weekly reminders of adherence, and side-effects reporting.

Healthcare workers aged 18 to 70 years were eligible if they did not have a prior diagnosis of SARS-CoV-2 infection, did not have symptoms compatible with SARS-CoV-2 infection, had a negative IgM/IgG test for SARS-CoV-2, had a negative HIV and (for women) pregnancy tests, a normal electrocardiogram (ECG), and no history of prolongation of the QT interval, maculopathy, impaired renal function, or immunosuppressive or hematologic conditions. Because women comprised the majority of healthcare workers, we ensured 40% of individuals screened for eligibility were males. Recruitment started in April 2020 in Spain, October 2020 in Bolivia, and March 2021 in Venezuela (Supplementary Figure 1) . The study ended on May 30, 2021.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (20) . Participants received treatment for 12 weeks (or until a SARS-CoV-2 infection was diagnosed), irrespective of symptoms, or the administrative end of the study, whichever occurred first. Investigators, participants, and the data analyst were unaware of treatment assignment.

The primary outcome was symptomatic COVID-19, defined as the presence of SARS-CoV-2 infection confirmed by a polymerase chain reaction (PCR) test plus any of the following symptoms: general malaise, fever, cough, joint pain, or breathing difficulty. PCR-confirmed asymptomatic SARS-CoV-2 infection was a secondary outcome. Other secondary outcomes (severity and duration of symptoms) could not be studied. We also studied the outcome "any (symptomatic or asymptomatic) COVID-19 infection", which had not been pre-specified in the study protocol.

Adverse events were ascertained in each monthly visit and weekly through app reminders.

Adverse events were classified as mild (easily tolerated), moderate (interference with normal activities), or severe (incapacitating, with inability to perform normal activities). Regardless of severity, adverse events were classified as serious if they required hospitalization, prolonged an existing hospitalization, or led to major or permanent disability. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We used the Kaplan-Meier estimator to obtain the cumulative risk for each outcome over 14 weeks of follow-up in each treatment group (over 95% of participants had attended their third monthly visit by 14 weeks after randomization). We compared the group-specific risks via differences and ratios with the placebo only group as the reference. In post-hoc analyses, we compared the risk in the two groups containing HCQ with the two groups not containing HCQ, and in the two groups containing TDF/FTC with the two groups not containing TDF/FTC. We calculated 95% confidence intervals using the percentile bootstrap method with 500 repetitions. In sensitivity analyses, we used a Cox proportional hazards model to estimate the hazard ratio of the two outcomes.

This study was approved by the institutional review boards of University Hospital de La Princesa, Madrid, Spain, Servicio Departamental de Salud de Chuquisaca in Bolivia, and Instituto Nacional de Higiene "Rafael Rangel" in Venezuela. An independent medical monitor and a data safety monitoring board provided oversight of safety and efficacy.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Of 1002 individuals screened for eligibility, 926 (92.4%) were eligible. The main reason for ineligibility was a previous COVID-19 diagnosis or compatible symptoms ( Figure 1 ).

Nineteen individuals withdrew or were lost to follow-up before treatment assignment. Of 907 randomized individuals, 220 were assigned to the TDF/FTC plus HCQ group (12 did not start treatment), 231 to the TDF/FTC placebo plus HCQ group (7 did not start treatment), 233 to the TDF/FTC plus HCQ placebo group (12 did not start treatment), and 223 to the double placebo group (12 did not start treatment). Of 696 individuals who completed the scheduled follow-up, 668 completed the scheduled treatment as indicated in the protocol.

Supplementary Tables 1 and 2 show the reasons for early termination of treatment and incomplete follow-up, respectively, by treatment group.

Baseline characteristics of the 907 participants are summarized in Table 1 and Supplementary   Table 3 . Their median age was 38 years (range 18 to 68 years) and 62.5% were female. Most participants worked at inpatient care facilities (62.3%) and the most frequent occupation was physician (30.5%). Comorbidities were rare. By country, 64.2% of participants were recruited in Spain, 22.3% in Bolivia, and 13.6% in Venezuela. Figure 2A shows the cumulative risk of symptomatic COVID-19 by treatment group. There were 14 cases: 3 in each group with active treatment and 5 in the placebo only group. All cases had mild symptoms that did not require hospitalization (Supplementary Table 4 ).

Compared with the placebo only group, the 14-week risk ratio (95% CI) of symptomatic COVID-19 was 0.39 (0.00, 1.98) for TDF+HCQ, 0.34 (0.00, 2.06) for TDF, and 0.49 (0.00, 2.29) for HCQ ( Table 2 ).

The 14-week risk ratio (95% CI) of symptomatic COVID-19 was 0.68 (0.10, 2.04) for the groups assigned to HCQ compared with the two groups not assigned to HCQ (Supplementary All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 5 and Supplementary Figure 2) , and 0.49 (0.09, 1.70) for the groups assigned to TDF/FTC compared with the two groups not assigned to TDF/FTC (Supplementary Table 6 and Supplementary Figure 3 ). Table 2 ).

The 14-week risk ratio (95% CI) of asymptomatic COVID-19 was 0.79 (0.47, 1.33) for the groups assigned to HCQ compared with the groups not assigned to HCQ (Supplementary Table 5 Table 2 ). The 14-week risk ratio (95% CI) of any COVID-19 diagnosis was 0.78 (0.49, 1.23) for the groups assigned to HCQ compared with the groups not assigned to HCQ (Supplementary Table 5 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The corresponding hazard ratios were similar (Supplementary Table 7 ).

The proportion of individuals with adverse events ranged between 21.1% in the placebo group and 31.3% in the TDF/FTC group. Most were mild and of gastrointestinal nature (Table 3 ). There were 5 serious adverse events: 4 in the placebo only group (hospital admission due to a bleeding uterine myoma, hospital admission due to smoke inhalation from a workplace fire, an episode of dizziness and bradypsiquia, and an episode of jaundice and vomiting) and 1 in the TDF/FTC +HCQ group (retinal detachment). None of the serious adverse events were linked to the study drugs.

In this randomized, double-blind, placebo-controlled clinical trial we evaluated the effect of treatment with HCQ and TDF/FTC, alone or in combination, as pre-exposure prophylaxis for symptomatic COVID-19 among health care workers after 12 weeks of follow-up. However, the trial recruited approximately a quarter of the intended number of participants and thus the effect estimates were imprecise: compared with placebo, the risk of symptomatic COVID-19 was lower in the groups assigned to HCQ or TDF/FTC, but effects between a 2-fold risk increase and perfect protection with HCQ or TDF/FTC were highly compatible with the data.

For any (symptomatic or asymptomatic) COVID-19, the risk in the group assigned to combined HCQ plus TDF/FTC was half the risk in the group assigned to placebo only, and effects between a 79% reduction in risk and no reduction in risk were highly compatible with the data.

EPICOS also confirmed HCQ and TDF/FTC were safe, with mostly mild adverse events of gastrointestinal nature. This was expected because, after decades of use, the safety record of low-dose HCQ and of TDF/FTC is well established (17) (18) (19) . TDF/FTC has been shown to be safe even when used during pregnancy (19) . All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 4, 2022. Several randomized, placebo-controlled clinical trials have studied HCQ, at different doses and with different outcome definitions, as pre-exposure prophylaxis for (mostly non-severe) COVID-19 in health care workers (2, (4) (5) . Like EPICOS, five of these trials could not achieve their intended sample size (4, 5) , partly because potential participants were averse to receive HCQ after poorly conducted observational studies (later retracted) (21) suggested HCQ was not safe, and the "nonsignificant" findings of small randomized trials for prophylaxis were misinterpreted as lack of a beneficial effect. However, all trials with more than 1000 patients found similar estimates: a COVID-19 hazard ratio of 0.73 (95% CI 0.48-1.09) for HCQ vs. placebo after 12 weeks of follow-up in a trial with 1483 participants (5) All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The findings from the EPICOS trial add to this growing evidence suggesting a beneficial effect of TDF/FTC in early SARS-CoV-2 infection. EPICOS also confirmed TDF/FTC is safe, as has been found over two decades of use, even in pregnant women (18) (19) . However, even if HCQ and TDF/FTC were effective as pre-exposure prophylaxis for COVID-19, the practical implications are currently limited because vaccines are a better approach to prevention when available, at least for the variants studied so far and for immunocompetent persons. The efficacy of vaccines seems to be reduced in immunocompromised patients who are in need of other prophylactic strategies (29).

A timelier question is whether HCQ and TDF/FTC could be used for early treatment of COVID-19 in non-hospitalized patients. The question has already been answered for HCQ (30) but not for TDF/FTC, a generic and inexpensive drug combination with the potential for massive worldwide production, and for which the available evidence supports the need for therapeutic trials.

In summary, this randomized, double-blind, placebo-controlled clinical trial in 907 health care workers could not rule out a beneficial effect of HCQ and TDF/FTC, alone or in (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 4, 2022. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  Any medication as prophylaxis against SARS-CoV-2 or HIV after March 1, 2020.  Treatment in the previous month and for >7 days with drugs that may prolong QT interval, including azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone, pentamidine, procainamide, quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone.  Pregnancy or plans to conceive during the study period.  Breastfeeding  Known allergy to any of the experimental medications or excipients All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 4, 2022. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 2 . Cumulative risk of symptomatic and asymptomatic COVID-19 HCQ-containing groups and groups without HCQ, EPICOS randomized trial All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 3 . Cumulative risk of symptomatic and asymptomatic COVID-19 in TDF/FTC-containing groups and groups without TDF/FTC, EPICOS randomized trial.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 4, 2022. ; https://doi.org/10.1101/2022.03.02.22271710 doi: medRxiv preprint

Division for HIV, STI, Viral Hepatitis and TB Control. Ministry of Health

Clinical trials for the prevention and treatment of COVID-19: current state of play

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial

Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19

Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ)

Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease

Healthcare Workers: A Randomized Trial

Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State

Measurement of antiretroviral drugs in the lungs of HIV-infected patients

Hydroxychloroquine in systemic lupus erythematosus (SLE)

How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP

Safety of Tenofovir Disoproxil Fumarate for Pregnant Women Facing the Coronavirus Disease

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder

Estimated 14-week risks of symptomatic, asymptomatic, and any COVID-19 diagnosis in HCQ-containing groups and groups without HCQ, EPICOS randomized trial

Cases / n 14-week risk (95% CI), % Risk difference (95% CI), % Risk ratio (95% CI)

Estimated 14-week risks of symptomatic, asymptomatic, and any COVID-19 diagnosis in TDF/FTC-containing groups and groups without TDF/FTC, EPICOS randomized trial

Cases / n 14-week risk (95% CI), % Risk difference (95% CI), % Risk ratio (95% CI)

Description of observed adverse events by system organ class: (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.